(Circulation. 1999;99:3079-3085.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
From the Department of Physiology (E.K.), Kaunas Medical University, Lithuania, and the Departments of Cardiovascular Surgery, Biochemistry and INSERM U-127 (J.P., C.M., J.-M.L., P.M.), Hôpital Lariboisière, Paris, France.
Correspondence to Philippe Menasché, MD, PhD, Department of Cardiovascular Surgery, Hôpital Lariboisière, 2, rue Ambroise Paré, 75475 Paris Cedex 10, France.
| Abstract |
|---|
|
|
|---|
-opioid receptors. This study was designed to
assess whether activation of these receptors could reproduce the
protection conferred by ischemic preconditioning and whether
such cardioprotection was similarly mediated by an opening of
ATP-sensitive potassium (KATP) channels.
Methods and ResultsThirty-two isolated rat hearts were arrested
with and stored in Celsior at 4°C for 5 hours before being reperfused
for 2 hours. They were divided into 4 equal groups. Group 1 hearts
served as controls. In group 2, ischemic preconditioning was
elicited by two 5-minute global ischemia periods interspersed
with 5 minutes of reperfusion before arrest. In group 3, hearts were
pharmacologically preconditioned with a 15-minute infusion of the
-opioid receptor agonist
D-Ala2-D-Leu5-enkephalin (DADLE; 200
µmol/L). In group 4, the protocol was similar to group 3 except that
infusion of DADLE was preceded by infusion of the KATP
blocker glibenclamide (50 µmol/L). The salutary effects of both
forms of preconditioning were primarily manifest as a better
preservation of diastolic function, a reduced myocardial
edema, and reduced creatine kinase leakage. This protection was
abolished by administration of glibenclamide before DADLE.
ConclusionsThese data suggest that activation of
-opioid
receptors improves recovery of cold-stored hearts to a similar extent
as ischemic preconditioning, most likely through an opening of
KATP channels. This provides a rationale for improving the
preservation of hearts for transplantation by pharmacologically
duplicating the common pathway to natural hibernation and
preconditioning.
Key Words: transplantation ischemia potassium receptors
| Introduction |
|---|
|
|
|---|
20% of early
deaths after heart transplantation.1 Although its origin
is multifactorial, an important role is likely to be played by
inadequate myocardial preservation throughout the
arrest/storage/implantation/reperfusion sequence to which the allograft
is exposed. Among the recent strategies that have been proposed to
enhance donor heart preservation, ischemic preconditioning is
generating a great deal of interest because of the consistent
cardioprotective effects associated with its use across a wide variety
of experimental models and animal species.2
However, because the induction of preconditioning by an
ischemic-type stimulus is rather unappealing,3
several studies have tried to identify the endogenous
mediators of this adaptive pathway in an attempt to use them as
pharmacological alternates. Although much interest has been paid to
adenosine4 and
1-adrenoceptor5 agonists, opioid
receptors have also been reported to trigger the preconditioning
pathway.6 7 8 Interestingly, opioid receptor stimulation
also seems to be involved in the enhancement of tissue survival
inherent in natural hibernation of mammals,9 10 a
situation that closely parallels that of cardiac allografts during the
cold-storage interval. The present study, performed in a rat model
of prolonged cold heart storage, was therefore designed to address the
following 3 questions: (1) Can activation of
-opioid receptors
improve the functional preservation of cold-stored hearts? (2) To what
extent does this protection compare with that conferred by classic
ischemic preconditioning? and (3) Is the opioid-linked
cardioprotection similarly mediated by an opening of ATP-sensitive
potassium (KATP) channels, which are currently
considered the main effectors of the ischemic preconditioning
pathway?
| Methods |
|---|
|
|
|---|
The pulmonary outflow tract was incised to allow drainage of the coronary effluent, and a catheter was placed through the apex of the left ventricle to drain the thebesian flow. A saline-filled latex balloon was inserted into the left ventricle through a left atriotomy for isovolumetric pressure measurements. Balloon pressures were recorded with a Statham P23 Id transducer (Spectramed Inc, Critical Care Division), and the left ventricular developed pressure signal was differentiated electronically (Gould-Statham 13-4615-71 differentiator, Spectramed Inc). All data were displayed on a 4-channel direct-writing recorder (Enertec). Coronary flow was measured by timed collection of the coronary venous effluent in a graduated cylinder. Left ventricular pacing was established at a constant rate of 320 bpm.
Experimental Time Course and Measurements
The hearts were initially allowed to equilibrate for 15 minutes.
The left ventricular balloon was then inflated to the
volume that gave an end-diastolic pressure of
8
mm Hg. Contractile function and coronary flow were measured in
triplicate under these isovolumic conditions. In addition, a left
ventricular pressure-volume curve was constructed by
incremental inflation of the balloon volume by 0.02-mL aliquots. Two
sets of pressure-volume measurements were generated, the first of which
was discarded because of small balloon shifts. Zero volume was defined
as the point at which the left ventricular
end-diastolic pressure was zero. On completion of the
pressure-volume curve, the left ventricular balloon was
deflated to set the end-diastolic pressure back to the
baseline value of 8 mm Hg. The
endothelium-dependent vasodilatory response was then
tested by a 5-minute perfusion of 5-hydroxytryptamine
(5-HT, 10-7 mol/L). Coronary flow was
measured during the last 4 minutes of 5-HT administration. This was
followed by a 12-minute washout period of drug-free Krebs buffer
perfusion. After a steady baseline coronary flow had been
reestablished, endothelium-independent vasodilation was
tested by infusion of papaverine (5x10-6 mol/L)
for 5 minutes, and coronary flow was again measured during the
last 4 minutes of this perfusion.
At the end of the control period, hearts were randomly assigned to 1 of the 4 experimental groups (see below). They were then arrested with 50 mL of Celsior, a new heart preservation solution,11 delivered at 4°C under a pressure of 60 cm H2O. Hearts were then removed from the perfusion apparatus and stored for 5 hours at 4°C in plastic containers filled with the same solution and surrounded by crushed ice.
On completion of the storage interval, hearts were transferred back to
the Langendorff column. The balloon catheter was reinserted into the
left ventricle and reinflated to the same volume as during the
preischemic period. Hearts were reperfused for 2 hours at
37°C. The reperfusion pressure was set at 50 cm
H2O during the initial 15 minutes of reflow,
after which it was raised back to 100 cm H2O for
the remainder of reperfusion. Pacing (at 320 bpm) was reinstituted once
a spontaneous regular heart rhythm was resumed. Isovolumic measurements
of contractile indexes and diastolic pressure were taken in
triplicate at 25, 35, and 45 minutes of reperfusion. At this time
point, 2 pressure-volume curves (the first of which was discarded) were
again generated over the same range of balloon volumes as used during
the acquisition of preischemic data. The
endothelium-dependent and -independent vasodilatory
responses to 5-HT and papaverine, respectively, were then tested
according to the same protocol as during the preischemic
period (and after adjustment of the balloon volume so as to reproduce
the end-diastolic pressure of
8 mm Hg). After 90
minutes of reperfusion, the constant-pressure heart model was converted
to a constant-flow preparation by use of a calibrated roller pump
(Minipuls 2, Gilson). Arterial pressure was measured
continuously by a pressure transducer connected to the aortic cannula,
and coronary resistance was calculated as arterial
pressure divided by coronary flow. After baseline measurements
were made at constant flow, the coronary bed was preconstricted
by a continuous infusion of prostaglandin
F2
(10-5 mol/L), which
yields a stable level of vasoconstriction. The
endothelium-dependent vasorelaxation to acetylcholine
(10-6 mol/L) was then tested. At the end of the
2-hour reperfusion interval, hearts were removed from the Langendorff
column and the ventricles weighed. Wet weights were determined after
excess fluid was blotted from specimens. Dry weights were determined
after the specimens were dried for 24 hours at 80°C. Water content
(%) was then computed as 100x(wet weight-dry weight)/wet weight.
In addition to measurements of function, flow, and edema, creatine kinase leakage in the collected coronary effluent was measured over the initial 45 minutes of reperfusion. Total creatine kinase activity was assessed enzymatically with an automatic analyzer (Olympus). The results are expressed as international units (IU) per gram of dry weight.
Experimental Groups
Four groups (8 hearts per group) were studied. The control group
was subjected only to storage and reperfusion, without any prearrest
intervention. In the ischemic preconditioning group, hearts
underwent two 5-minute global ischemia periods interspersed
with 5 minutes of reperfusion before arrest. In the third group, hearts
were pharmacologically preconditioned with a 15-minute infusion of the
-opioid receptor agonist
D-Ala2-D-Leu5-enkephalin (DADLE; 200
µmol/L) added to the perfusate before arrest. Because DADLE
is rapidly degraded in vivo, this concentration was selected to largely
exceed the Ki for the drug and consequently
increase the likelihood of maximal efficacy. The same protocol as in
group 3 was followed in the fourth group of hearts except that the
administration of DADLE was preceded by a 5-minute infusion of the
KATP blocker glibenclamide (50
µmol/L).
Solutions and Drugs
The Krebs-Henseleit buffer was prepared fresh the day of use and
contained (in mmol/L): NaCl 118; KCl 4.7;
MgSO4 1.2; NaHCO3 25;
KH2PO4 1.2;
CaCl2 2.5; and glucose 11. Celsior solution was
provided by Imtix. The composition of the solution is detailed
in Table 1
. The
-agonist DADLE
was purchased from Bachem Biochimie. All other chemicals (5-HT,
papaverine, acetylcholine, prostaglandin
F2
, and glibenclamide) were obtained from
Sigma Chemical Co. Glibenclamide was prepared as stock solution in
dimethyl sulfoxide (the final concentration of which was <0.05%). The
other drugs were dissolved in Krebs-Henseleit buffer immediately before
use.
|
Statistical Analysis
Functional data were compared by 2-factor ANOVA with repeated
measures, with treatment group as 1 factor and time as the second. When
calculated values of F exceeded tabular values of the 5% level,
intergroup differences were specified by use of a post hoc Student
t test with Bonferroni correction for multiple comparisons.
Compliance curves were assessed by linear regression analysis
of the end-diastolic pressure data to calculate a slope.
Linear regression provided a reasonable model for the
diastolic function curves
(R2 of 0.88 to 0.98). Coronary
flows, creatine kinase leakage, and myocardial water content were
compared among the 4 groups by unpaired t tests. A
P value <0.05 was considered significant. Data are reported
as mean±SEM.
| Results |
|---|
|
|
|---|
|
|
In contrast, neither form of preconditioning improved postarrest
systolic function over that of control or glibenclamide and
DADLEtreated hearts. In the 4 groups, reperfusion values of developed
pressure and dP/dt were reduced by
50% compared with baseline
levels without significant between-group differences (Table 2
).
Coronary Vascular Responsiveness
Before storage, administration of 5-HT significantly increased
coronary flow above baseline values (P<0.001 in all
groups). During reperfusion, 5-HT still elicited a significant increase
in coronary flow, but this
endothelium-dependent response was smaller than before
storage (P<0.05 versus baseline values). There was no
significant difference in the poststorage response to 5-HT among the 4
groups (Figure 2
). Within-group changes
in the endothelium-independent response to papaverine
featured slightly different patterns (Table 3
). Thus, before storage, papaverine
caused an increase in coronary flow that was of similar extent
in all groups (P<0.001 versus baseline). Conversely, after
storage, papaverine-induced vasodilation was of greater magnitude in
the 2 preconditioned groups (P<0.02 versus baseline) than
in control hearts or hearts pretreated with glibenclamide before DADLE
infusion (P<0.05 versus baseline). In the constant-flow
experiments, the endothelium-dependent vasodilatory
response to acetylcholine was not significantly different among the 4
groups (Table 4
).
|
|
|
Myocardial Water Content
Percent tissue water was significantly greater in control hearts
(81.23±0.23%) and in hearts pretreated by glibenclamide before DADLE
infusion (80.90±0.13%) than in hearts preconditioned by either
ischemia (79.88±0.22%) or DADLE-induced activation of
-opioid receptors (79.46±0.37%; for these 2 preconditioning
groups, P<0.001 versus controls and P<0.005
versus glibenclamide plus DADLE).
Creatine Kinase Leakage
In keeping with functional data, both forms of preconditioning
presumably resulted in infarct limitation, because creatine kinase
leakage during the initial 45 minutes of reperfusion was significantly
lower in ischemically preconditioned hearts (345±54 IU/g dry
weight) and DADLE-preconditioned hearts (379±62 IU/g dry weight) than
in controls (548±79 IU/g dry weight; P<0.001 versus the 2
preconditioned groups). Administration of glibenclamide before DADLE
blunted this protective effect, because in this group,
postischemic enzyme release increased to 453±43 IU/g dry
weight. This difference compared with the 2 preconditioned groups
failed, however, to reach the level of statistical significance
(P=0.18).
| Discussion |
|---|
|
|
|---|
-opioid receptors improves the
functional preservation of cold-stored hearts (as occurs during
transplantation). (2) This improvement is of similar magnitude as that
conferred by 2 brief cycles of classic ischemic
preconditioning. (3) The opioid-linked cardioprotective pathway is
likely to involve an opening of KATP channels,
because it is abolished by glibenclamide. Because this
receptor-mediated mechanism displays close similarities with the one
involved in natural hibernation, a closer look at the biology of this
unique phenomenon might provide useful clues for improving the
preservation of heart transplants.
Endogenous Mediators of Natural Hibernation
The tolerance of hibernating animals to extended periods of cold
hypoxia is attributed to a plasma factor (hibernation-induction
trigger), the opiate nature of which is supported by 2 major lines of
evidence: (1) the behavioral and physiological
changes induced in primates by
intracerebroventricular infusion of the
hibernation-induction trigger present in the blood of hibernating
woodchucks are reversed or delayed by opiate
antagonists,9 and (2) the ability of the
hibernation-induction trigger to induce hibernation can be mimicked by
the
-opioid receptor agonist DADLE, whereas µ- and
-opioids are
ineffective.10 Likewise, both hibernation-induction
trigger and DADLE have been shown to similarly improve protection in
animal models of multiorgan block autoperfusion12 or
cardioplegic arrest.13
Endogenous Mediators of Preconditioning
The cardioprotective effects of preconditioning are well
established and are primarily manifest as a reduction in infarct size
and, through this mechanism, an improvement in postischemic
function.14 That prolonged storage of heart transplants
could represent an elective indication of preconditioning
interventions is supported by the study of Karck and
coworkers,15 who have shown, in rat hearts cold-stored for
10 hours, that a 5-minute preconditioning episode before arrest
significantly improved recovery of function and concomitantly reduced
creatine kinase leakage. The results yielded by our group of
ischemically preconditioned hearts support this hypothesis.
However, safety concerns about inflicting an ischemic insult to
the heart3 justify the ongoing search for pharmacological
mimetics.
According to the current scheme, the preconditioning signal
activates various membrane receptors, which trigger an
intracellular signaling pathway leading to the activation of several
kinases, in particular protein kinase C (PKC). This, in turn, causes
opening of the KATP channels, possibly at the
mitochondrial level,16 17 with subsequent protection
through limitation of calcium overload and/or better control of
cellular volume. Recent studies have highlighted that in addition to
adenosine and
1-agonists,4 5 opioids also play
an important role in mediating preconditioning-induced
cardioprotection.6 7 8
Cardioprotective Effects of Opioid Receptor Activation
The role of opioids in preconditioning is based on the observation
that their infarct-limiting effect can be mimicked by an infusion of
morphine, a nonspecific agonist of µ-receptors, in both
rat6 and rabbit7 hearts. It was demonstrated
that ischemic preconditioning in the intact rat heart is
mediated by
- (probably the
-1
subtype8 18 ) but not µ- or
-opioid
receptors.8 The present study shows that these
observations, made in models of regional ischemia, can be
extended to the setting of global ischemic arrest, because the
functional preservation conferred to cold-stored rat hearts by
ischemic preconditioning could be reproduced by a selective
DADLE-induced activation of
-opioid receptors. Equally successful
results with DADLE pretreatment have been reported in rabbit hearts
subjected to a similar protocol of prolonged cold
storage.19 Interestingly, in the latter experiments, DADLE
was ineffective when given only as an additive to the arrest solution,
which supports the concept that opioid receptor activation acts by
preconditioning the heart before the onset of the ischemic
interval.
Opioid receptors are indeed present in cardiac myocytes,20 and at least 3 mechanisms can account for their cardioprotective effects: (1) an increased production of inositol 1,4,5-triphosphate (IP3) and a subsequent depletion of the sarcoplasmic reticulum from its calcium stores,21 which might then reduce cytosolic calcium accumulation during sustained ischemia; (2) an activation of PKC by diacylglycerol, a compound formed in addition to IP3 from the hydrolysis of membrane inositol-containing phospholipids and the subsequent PKC-mediated opening of KATP channels22 ; and (3) a direct, PKC-independent opening of these channels.23 Thus, regardless of the mechanism, activation of KATP channels appears to be the final effector of the opioid-coupled cardioprotective transduction pathway. Additional evidence for their involvement is provided by the ability of glibenclamide to antagonize the cardioprotection elicited by morphine6 or, as in the present study, by DADLE preconditioning. We acknowledge that because glibenclamide (in contrast to 5-hydroxydecanoate) is a nonspecific blocker of KATP channels, our data do not enable us to determine which fraction (sarcolemmal or mitochondrial) of these channels was involved. This, however, does not alter the conclusion pertaining to their role in mediating the opioid-triggered cardioprotective pathway. The reduction in calcium overload expected from such an opening of KATP channels (regardless of their cellular location) is indeed consistent with our finding of an improved preservation of diastolic function in DADLE-preconditioned hearts.
The expected reduction of calcium overload associated with DADLE preconditioning should in turn limit the breakdown of ATP. Indeed, both hibernation-induction trigger and DADLE preserve myocardial levels of ATP.19 This should result in better functioning of energy-driven ion pumps, particularly sarcolemmal sodium/potassium ATPase activity,24 and could thus account for the lesser degree of myocardial edema seen in the DADLE-preconditioning group.
Conversely, opioid receptor stimulation failed to improve preservation of endothelium-dependent coronary responsiveness beyond that seen in the control group. This result is consistent with the data of Bauer and coworkers25 showing that ischemic preconditioning was unable to prevent the deterioration of myocardial blood flow and the loss in the endothelium-dependent vasodilation seen during reperfusion. Likewise, Shirai and associates26 recently reported that preconditioning reduced injury in cardiomyocytes but not endothelial cells. It is noteworthy that the endothelium-dependent response to 5-HT, although of smaller magnitude than before ischemia, was still present during reperfusion in all groups, which is consistent with the ability of the antioxidant content of Celsior to preserve endothelial function after prolonged cold heart storage.27 Furthermore, the trend toward better preservation of the endothelium-independent vasodilatory response in hearts preconditioned by ischemia or DADLE might be related to the lesser degree of postischemic myocardial contracture seen in these 2 groups.28
Clinical Implications and Limitations
From a practical standpoint, the opioid-linked transduction
pathway could be therapeutically exploited by acting on its trigger
(the opioid receptor) or its putative effector (the
KATP channel). In surgical practice, opioid
receptor stimulation implemented shortly before the ischemic
interval may be less effective than expected because of the almost
universal use of fentanyl-based anesthesia. Fentanyl is a
nonspecific µ-opioid agonist that, on the basis of right atrial
biopsy samples taken from patients at the onset of
cardiopulmonary bypass, results in full opioid receptor
occupancy and thus leaves little, if any, room available for further
activation by a
-agonist (J.-M. Launay, MD, unpublished data,
1998). Furthermore, opioid-coupled transduction pathways can be
fundamentally different depending on the type of agonist, and fentanyl,
in contrast to morphine, does not seem to result in
KATP channel opening.29 It is thus
possible that interventions directly targeted at opening these channels
might be more promising, whether based on the currently available drug
nicorandil,30 the mitochondrial KATP
channel opener diazoxide,16 17 or anesthetics like
isoflurane.31
We acknowledge the limitations of our model, in particular the use of an isolated heart preparation, the nonheme nature of the perfusate, and the relatively brief period of postischemic observation. Nevertheless, these models have proven to be fairly reliable for screening myocardial preservative strategies. Thus, the present results strongly suggest that opioid receptor stimulation and opening of KATP channels are effective approaches for pharmacologically duplicating the cardioprotective effects of ischemic preconditioning. It is tempting to speculate that their use in heart transplantation would be nothing but the logical exploitation of the mechanisms accounting for maintenance of tissue survival during natural hibernation.
| Acknowledgments |
|---|
Received November 18, 1998; revision received March 29, 1999; accepted March 30, 1999.
| References |
|---|
|
|
|---|
2. Parratt JR. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci. 1994;15:1925.[Medline] [Order article via Infotrieve]
3.
Perrault LP, Menasché P, Bel A, Chaumaray T,
Peynet J, Mondry A, Olivero P, Emanoil-Ravier R, Moalic J-M.
Ischemic preconditioning in cardiac surgery: a word of caution.
J Thorac Cardiovasc Surg. 1996;112:13781386.
4. Liu GS, Jacobson KA, Downey JM. An irreversible A1-selective adenosine agonist preconditions rabbit heart. Can J Cardiol. 1996;12:517521.[Medline] [Order article via Infotrieve]
5.
Banerjee A, Locke-Winter C, Rogers KB, Mitchell MB,
Brew EC, Cairns CB, Bensard DD, Harken AH. Preconditioning against
myocardial dysfunction after ischemia and reperfusion by
an
1-adrenergic mechanism. Circ
Res. 1993;73:656670.
6.
Schultz JEJ, Hsu AK, Gross GJ. Morphine mimics the
cardioprotective effect of ischemic preconditioning via a
glibenclamide-sensitive mechanism in the rat heart. Circ
Res. 1996;78:11001104.
7. Chien GL, Van Winkle DM. Naloxone blockade of myocardial ischemic preconditioning is stereoselective. J Mol Cell Cardiol. 1996;28:18951900.[Medline] [Order article via Infotrieve]
8.
Schultz JEJ, Hsu AK, Gross GJ. Ischemic
preconditioning in the intact rat heart is mediated by
1- but not µ- or
-opioid receptors.
Circulation. 1998;97:12821289.
9. Oeltgen PR, Walsh JW, Hamann SR, Randall DC, Spurrier WA, Myers RD. Hibernation "trigger": opioid-like inhibitory action on brain function of the monkey. Pharmacol Biochem Behav. 1982;17:12711274.[Medline] [Order article via Infotrieve]
10. Oeltgen PR, Nilekani SP, Nuchols PA, Spurrier WA, Su T-P. Further studies on opioids and hibernation: delta opioid receptor ligand selectively induced hibernation in summer-active ground squirrels. Life Sci. 1988;43:15651574.[Medline] [Order article via Infotrieve]
11. Menasché P, Termignon J-L, Pradier F, Grousset C, Mouas C, Alberici G, Weiss M, Piwnica A, Bloch G. Experimental evaluation of Celsior, a new heart preservation solution. Eur J Cardiothorac Surg. 1994;8:207213.[Abstract]
12.
Chien S, Oeltgen PR, Diana JN, Salley RK, Su T-P.
Extension of tissue survival time in multiorgan block preparation with
a delta opioid DADLE ([D-Ala2,
D-Leu5]-enkephalin). J Thorac
Cardiovasc Surg. 1994;107:964967.
13.
Bolling SF, Tramontini NL, Kilgore KS, Su T-P, Oeltgen
PR, Harlow HH. Use of "natural" hibernation induction triggers for
myocardial protection. Ann Thorac Surg. 1997;64:623627.
14.
Faris B, Peynet J, Wassef M, Bel A, Mouas C, Duriez M,
Menasché P. Failure of preconditioning to improve
postcardioplegia stunning of minimally infarcted hearts. Ann
Thorac Surg. 1997;64:17351741.
15. Karck M, Rahmanian P, Haverich A. Ischemic preconditioning enhances donor heart preservation. Transplantation. 1996;62:1722.[Medline] [Order article via Infotrieve]
16.
Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN,
Darbenzio RB, D'Alonzo AJ, Lodge NJ, Smith MA, Grover GJ.
Cardioprotective effect of diazoxide and its interaction with
mitochondrial ATP-sensitive K+ channels: possible
mechanism of cardioprotection. Circ Res. 1997;81:10721082.
17.
Sato T, O'Rourke B, Marbán E. Modulation of
mitochondrial ATP-dependent K+ channels by
protein kinase C. Circ Res. 1998;83:110114.
18.
Schultz JEJ, Hsu AK, Nagase H, Gross GJ. TAN-67, a
1-opioid receptor agonist, reduces infarct
size via activation of Gi/o proteins and
KATP channels. Am J Physiol. 1998;274:H909H914.
19. Bolling SF, Su T-P, Childs KF, Ning X-H, Horton N, Kilgore K, Oeltgen PR. The use of hibernation induction triggers for cardiac transplant preservation. Transplantation. 1997;63:326329.[Medline] [Order article via Infotrieve]
20. Ventura C, Bastagli L, Bernardi P, Caldarera CM, Guarnieri C. Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. Biochim Biophys Acta. 1989;987:6974.[Medline] [Order article via Infotrieve]
21.
Ventura C, Spurgeon H, Lakatta EG, Guarnieri C,
Capogrossi CM.
and
opioid receptor stimulation affects
cardiac myocyte function and Ca2+ release from an
intracellular pool in myocytes and neurons. Circ Res. 1992;70:6681.
22.
Light PE, Sabir AA, Allen BG, Walsh MP, French RJ.
Protein kinase C-induced changes in the stoichiometry of ATP binding
activate cardiac ATP-sensitive K+
channels. Circ Res. 1996;79:399406.
23.
North RA, Williams JT, Surprenant A, Christie MJ.
µ and
receptors belong to a family of receptors that are coupled
to potassium channels. Proc Natl Acad Sci U S A. 1987;84:54875491.
24.
Nawada R, Murakami T, Iwase T, Nagai K, Morita Y,
Kouchi I, Akao M, Sasayama S. Inhibition of sarcolemmal
Na+, K+-ATPase activity
reduces the infarct size-limiting effect of preconditioning in rabbit
hearts. Circulation. 1997;96:599604.
25.
Bauer B, Simkhovich BZ, Kloner RA, Pryklenk K. Does
preconditioning protect the coronary vasculature from
subsequent ischemia/reperfusion injury? Circulation. 1993;88:659672.
26.
Shirai T, Rao V, Weisel RD. Preconditioning human
cardiomyocytes and endothelial cells.
J Thorac Cardiovasc Surg. 1998;115:210219.
27. Kevelaitis E, Nyborg N, Menasché P. Protective effect of reduced glutathione on endothelial function of coronary arteries subjected to prolonged cold storage. Transplantation. 1997;64:660663.[Medline] [Order article via Infotrieve]
28. Kevelaitis E, Mouas C, Menasché P. Poststorage diastolic abnormalities of heart transplants: is vascular dysfunction or myocardial contracture the culprit? J Heart Lung Transplant. 1996;15:461469.[Medline] [Order article via Infotrieve]
29. Raffa R, Martinez RP. The "glibenclamide-shift" of centrally-acting antinociceptive agents in mice. Brain Res. 1995;677:277282.[Medline] [Order article via Infotrieve]
30.
Menasché P, Kevelaitis E, Mouas C, Grousset C,
Piwnica A, Bloch G. Preconditioning with potassium channel openers: a
new concept for enhancing cardioplegic protection? J Thorac
Cardiovasc Surg. 1995;110:16061614.
31.
Kersten JR, Schmeling TJ, Hettrick DA, Pagel PS, Gross
GJ, Warltier DC. Mechanism of myocardial protection by isoflurane.
Anesthesiology. 1996;85:794807.In a rat model of
prolonged cold heart storage, activation of
-opioid receptors, as
occurs during natural hibernation, improves recovery of
diastolic function and reduces myocardial edema and
creatine kinase release to a similar extent as classic ischemic
preconditioning. This protective effect was abolished by the prior
administration of glibenclamide and most likely involves opening of
ATP-sensitive potassium channels.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
![]() |
D. V. Cuong, N. Kim, J. B. Youm, H. Joo, M. Warda, J.-W. Lee, W. S. Park, T. Kim, S. Kang, H. Kim, et al. Nitric oxide-cGMP-protein kinase G signaling pathway induces anoxic preconditioning through activation of ATP-sensitive K+ channels in rat hearts Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1808 - H1817. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Garcia-Dorado, A. Rodriguez-Sinovas, M. Ruiz-Meana, J. Inserte, L. Agullo, and A. Cabestrero The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion Cardiovasc Res, May 1, 2006; 70(2): 274 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Smith Sonneborn, H. Gottsch, E. Cubin, P. Oeltgen, and P. Thomas Alternative Strategy for Stress Tolerance: Opioids J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2004; 59(5): B433 - B440. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Buehler, A. Martire, C. Strohm, S. Wolfram, B. Fernandez, M. Palmen, X. H.T Wehrens, P. A Doevendans, W. M Franz, W. Schaper, et al. Angiogenesis-independent cardioprotection in FGF-1 transgenic mice Cardiovasc Res, September 1, 2002; 55(4): 768 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Sigg, J. A. Coles Jr., P. R. Oeltgen, and P. A. Iaizzo Role of delta -opioid receptor agonists on infarct size reduction in swine Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H1953 - H1960. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. Zingman, D. M. Hodgson, M. Bienengraeber, A. B. Karger, E. C. Kathmann, A. E. Alekseev, and A. Terzic Tandem Function of Nucleotide Binding Domains Confers Competence to Sulfonylurea Receptor in Gating ATP-sensitive K+ Channels J. Biol. Chem., April 12, 2002; 277(16): 14206 - 14210. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Karck, S. Tanaka, S. F. Bolling, A. Simon, T.-P. Su, P. R. Oeltgen, and A. Haverich Myocardial protection by ischemic preconditioning and {delta}-opioid receptor activation in the isolated working rat heart J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 986 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Sigg, J. A. Coles Jr, W. J. Gallagher, P. R. Oeltgen, and P. A. Iaizzo Opioid preconditioning: myocardial function and energy metabolism Ann. Thorac. Surg., November 1, 2001; 72(5): 1576 - 1582. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schulz, M. V Cohen, M. Behrends, J. M Downey, and G. Heusch Signal transduction of ischemic preconditioning Cardiovasc Res, November 1, 2001; 52(2): 181 - 198. [Full Text] [PDF] |
||||
![]() |
E. Kevelaitis, A. P. Patel, A. Oubenaissa, J. Peynet, C. Mouas, D. M. Yellon, and P. Menasche Backtable heat-enhanced preconditioning: a simple and effective means of improving function of heart transplants Ann. Thorac. Surg., July 1, 2001; 72(1): 107 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schulz, P. Gres, and G. Heusch Role of endogenous opioids in ischemic preconditioning but not in short-term hibernation in pigs Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H2175 - H2181. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Bell, M. N. Sack, A. Patel, L. H. Opie, and D. M. Yellon Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2296 - 2302. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takasaki, R. A. Wolff, G. L. Chien, and D. M. van Winkle Met5-enkephalin protects isolated adult rabbit cardiomyocytes via delta -opioid receptors Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2442 - H2450. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. P. Perrault and P. Menasche Preconditioning: can nature’s shield be raised against surgical ischemic-reperfusion injury? Ann. Thorac. Surg., November 1, 1999; 68(5): 1988 - 1994. [Abstract] [Full Text] [PDF] |
||||
![]() |
M POULLIS Diamorphine and British cardiology: so we are right! Heart, November 1, 1999; 82(5): 645 - 646. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |